Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from the last administration of Fate Therapeutics genetically modified NK cell product, subjects will be assessed for long-term safety and survival through questionnaires and blood tests.


Clinical Trial Description

This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who received a Fate Therapeutics NK cell product that has been modified by lentivirus-mediated genetically engineering. The period of follow-up is 15 years after the administration of the NK cell product. The study involves up to 15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated gene transfer in Fate Therapeutics clinical studies. Upon withdrawal or completion of the parent interventional study, the study site will contact the subject/healthcare provider/legal guardian annually. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04093622
Study type Observational
Source Fate Therapeutics
Contact
Status Terminated
Phase
Start date October 4, 2019
Completion date April 9, 2020

See also
  Status Clinical Trial Phase
Completed NCT04932967 - Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
Not yet recruiting NCT02900768 - Effects of Exercise on Allogeneic Stem Cell Transplant N/A
Recruiting NCT04082910 - Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Phase 1/Phase 2
Recruiting NCT05510089 - Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies N/A
Recruiting NCT06225856 - An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies Phase 1
Recruiting NCT06106360 - A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Recruiting NCT02828462 - Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
Completed NCT01714180 - Effect of Body Mass on Acyclovir Pharmacokinetics N/A
Completed NCT03241550 - A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients Phase 1
Active, not recruiting NCT04684108 - SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies Phase 1
Completed NCT02598752 - Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Completed NCT02880709 - The Effect of Special Diets in Hematological Cancer Patients Phase 4
Completed NCT00894049 - A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation Phase 2
Completed NCT04687982 - Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002). N/A
Completed NCT00897260 - Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders N/A
Recruiting NCT03850366 - HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Phase 2
Not yet recruiting NCT06066255 - PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM Phase 2
Enrolling by invitation NCT05364359 - Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy N/A
Recruiting NCT04841447 - Membrane Target Detection for Leukemia Treatment
Not yet recruiting NCT06279585 - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD N/A